Fangsheng Pharmaceutical’s IPO Application Been Approved

2014-10-23

In a statement at the evening of October 22nd, the IPO application of Hunan Fangsheng Pharmaceutical Co., Ltd. (Fangsheng Pharmaceutical) was approved by the CSRC.Edv九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Fangsheng Pharmaceutical, founded in 2002 and restructured in September 2009, is specialized in manufacturing Panax notoginseng Saponins, Cefixime tablets and pediatric drugs. It has been rated as Hunan High-tech Enterprise, Hunan Quality Credit AAA Enterprise, Hunan Third-batch Innovation Pilot Enterprise, Changsha Innovation Demonstration Enterprise 2012, etc. Edv九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

In 2010, JD Capital’s medical fund invested 60 million yuan in the company to take 15% of its shares, becoming its second largest shareholder.Edv九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

Since China reopened the market for initial public offerings, UTour Travel, FEITIAN, Liuzhou Pharmaceutical and IDEAR HANYU invested by JD Capital have been listed or prepared to be listed. In addition, Jianeng Energy has completed a backdoor listing after buying Huafang Textile and Sino Great Wall has announced its backdoor listing scheme through buying Shenzhen Victor Onward Textile.Edv九鼎投资(600053.SH)_上交所私募股权投资领域上市公司


Edv九鼎投资(600053.SH)_上交所私募股权投资领域上市公司

EN | CN